Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.
📌 Key Takeaways
- Based on the announcement, here are the key points regarding Eli Lilly's new program:
- **New Direct-to-Employer Program:** Eli Lilly is launching a initiative aimed directly at U.S. employers and their health plans to improve coverage of its obesity medications, such as Zepbound.
- **Addressing Coverage Gaps:** The program is a response to the common exclusion of obesity drugs from employer-sponsored insurance plans, which has been a major barrier to patient access despite the drugs' FDA approval and clinical benefits.
- **Focus on Value and Outcomes:** The company intends to offer tools and support to help employers understand the long-term value of covering these treatments, potentially highlighting how treating obesity can reduce other healthcare costs associated with weight-related conditions.
- **Strategic Market Move:** This direct employer outreach is a strategic effort by Eli Lilly to expand the market for its blockbuster obesity drugs by circumventing traditional payer reluctance and building demand from the plan sponsor level.
📖 Full Retelling
Employers can use Lilly's platform to connect with different third-party program administrators that help manage obesity treatment benefits and costs.
📚 Related People & Topics
Eli Lilly
American pharmacist, Union Army officer, businessman, philanthropist (1838–1898)
Eli Lilly (July 8, 1838 – June 6, 1898) was an American Union Army officer, pharmacist, chemist, and businessman who founded Eli Lilly and Company. Lilly enlisted in the Union Army during the American Civil War and recruited a company of men to serve with him in the 18th Independent Battery Indiana ...
Entity Intersection Graph
Connections for Eli Lilly:
🌐
Tirzepatide
3 shared
🏢
Novo Nordisk
3 shared
🌐
Psoriasis
2 shared
🌐
Ixekizumab
2 shared
🌐
Combination therapy
1 shared
Mentioned Entities
Original Source
In this article LLY Follow your favorite stocks CREATE FREE ACCOUNT The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike Blake | Reuters Eli Lilly on Thursday launched a new program designed to help more employers cover obesity drugs in the U.S., targeting a major barrier to access for patients. Lilly and its chief rival, Novo Nordisk , have moved to slash the cash prices of their popular obesity injections for those who want to pay entirely out-of-pocket. But employer coverage of obesity drugs remains uneven due to high costs, leaving roughly half of people with commercial insurance unable to start or stay on treatment, Lilly said in a release. List prices for Lilly's weight loss and diabetes treatments, Zepbound and Mounjaro, top $1,000 per month. Nearly one-fifth of firms with over 200 workers, including 43% with 5,000 or more workers, said they cover GLP-1 drugs for weight loss as of October, according to a survey by the Peterson-KFF Health System Tracker. "I think we'll learn in the coming months ahead, if this is a solution that maybe enables some employers who have been sitting on the sidelines to opt into obesity coverage for their employees," Kevin Hern, senior vice president of Lilly Employer, said in an interview. He added that some employers could opt to add coverage in the upcoming months, while others could wait until 2027. Eli Lilly's new "Employer Connect" platform gives employers more flexibility in how they cover obesity treatments, aiming to broaden employee access to the drugs at low out-of-pocket costs, while also limiting expenses for companies. Hern said the program addresses some of the "core tensions" for employers when considering coverage of obesity drugs, including transparency around drug prices, flexibility in benefits design and the ability to choose among independent administrators. Through the program, employers can pay a net discounted price of $449 per month for a new multi-dose for...
Read full article at source